SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hyrulean King who wrote (1812)6/25/1998 6:12:00 PM
From: george willse  Read Replies (1) of 5402
 
Anyone -

Not to change the subject, but I noticed a couple of posts that referred to testing in Japan. I beleive 185 individuals were tested with no serious side affects.

If this is the case, is SGNC actively pursuing the marketing/sale of the drug in Japan (as well as other countries)? One estimate I read said it will take ~3 years to be approved in the US. Other countries are less stringent and approve these types of products faster. The bottom line: is SGNC going to market outside the US ASAP to generate revenue, or is this still too early in the development phase?

Thanks,

George

BTW, I own SGNC stock (as well as DGIV, INFE and MTEI). This is however, my first post on this thread :-}
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News